Related Experiment Video
Updated: Jun 21, 2026
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
An open-label, Phase I study of cediranib (RECENTIN) in patients with acute myeloid leukemia
Walter Fiedler1, Rolf Mesters, Michael Heuser
1Department of Oncology, Hematology, BMT with section Pneumology Hubertus Wald Tumorzentrum - University Cancer Center Hamburg University Medical Center Hamburg Eppendorf 20246 Hamburg, Germany. Fiedler@uke.uni-hamburg.de
Abstract:
VEGFR and c-Kit signaling pathways may contribute to the pathophysiology of acute myeloid leukemia (AML). Thirty-five patients with AML received cediranib (RECENTIN), an oral, highly potent VEGF signaling inhibitor with c-Kit activity, at doses of < or =30 mg/day. The most common adverse events were diarrhea, hypertension and fatigue. Six patients experienced an objective response (3 each at 20 and 30 mg). Dose- and time-dependent reductions in sVEGFR-2 were observed, and there was a positive correlation between cediranib exposure and the change in plasma VEGF levels from baseline. Cediranib was generally well tolerated and showed preliminary evidence of activity as a monotherapy.